Congestive heart failure or irregular heart rhythms (arrhythmias) occur in all people with Duchenne muscular dystrophy by age 18. Chest and back deformities (scoliosis). Enlargement of the calf ...

Developed by Sarepta Therapeutics, Elevidys is a one-time, intravenous treatment that uses adeno-associated virus (AAV) ...

(1) The most common and severe form of muscular dystrophy among children, primarily boys, is Duchenne muscular dystrophy ... and having enlarged calf muscles from scar tissue buildup and ...

Scientists present current evidence for a new gene therapy for Duchenne muscular dystrophy called delandistrogene moxeparvovec.

Sarepta Therapeutics (NASDAQ:SRPT) and its partner Roche (OTCQX:RHHBY) received a 'go ahead' from the regulatory body in U.K.

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD), setting it on course to become the first non-steroidal ...

After months of uncertainty and controversy, the FDA has given approval to Sarepta's Duchenne muscular dystrophy drug – even though it hasn't yet shown any proof it can slow progress of the ...

Chronic muscle inflammation in Duchenne muscular dystrophy (DMD) is driven by both infiltrating and resident macrophages, the latter stimulated by CSF-1 produced by fibro/adipogenic progenitors.

The FDA has not identified any potential review issues. Also Read: Capricor Therapeutics Says Duchenne Muscular Dystrophy Candidate Shows Sustained Cardiac, Skeletal Benefits After 3 Years The BLA ...

provides statistically and clinically meaningful treatment benefits in individuals with Duchenne muscular dystrophy (DMD) If approved by the European Commission, Duvyzat will be available for ...